Target ALS fosters collaboration by exclusively funding multi-investigator research consortia that pursue novel approaches for ALS drug discovery and development.
Scientific Tools and Resources
ALS researchers worldwide have access to a range of critical tools ranging from biospecimens to genomic datasets to stem cells with no strings attached.
Engagement Between Academia and Industry
Target ALS offers the pharma/biotech industry access to its funding and resources to promote collaborative research projects across academia and industry and to seed ALS drug discovery programs in the industry.
No Intellectual Property Restrictions
Target ALS does not place any intellectual property (IP) restrictions on data generated by its funded research projects or scientific tools and resources, helping to facilitate the organization’s collaborative approach.
High-Impact Networking and Communication
Target ALS fosters ongoing networking and communication between scientists in academia and the pharmaceutical and biotech industries, among other stakeholders. This includes an annual summit in Cambridge, MA attended by 300+ scientists, foundations, venture capitalists, industry leaders and donors.
Join Us to Change the Prognosis for Patients
For the first time in the 150+ year history of this disease, we face a historic opportunity to radically change the prognosis for patients.
With your support, Target ALS can expand the Innovation Ecosystem, further advancing the development of new therapies that can be translated rapidly into the clinic and aid in the discovery of much-needed ALS Biomarkers.
Together, we can achieve historic breakthroughs and change the prognosis for patients.